The KEYNOTE-522 trial resulted in the recent approval of pembrolizumab in the neoadjuvant chemotherapy setting in TNBC regardless of PD-L1 status.24 Collectively, these observations suggest that biomarkers are needed to stratify patients for these therapies, especially for ER+ breast cancer with lower response rates. This evidence concerns the gene ESR1 and breast cancer.